August 31, 2021 -- Adaptive Phage Therapeutics (APT) has signed a licensing agreement with the Walter Reed Army Institute of Research (WRAIR) to gain access to its phage database.
The deal, which is synergistic with APT's ongoing partnership with the U.S. Navy, provides APT with access to the phage database of the U.S. military to treat critically ill patients. The opportunity to work with the U.S. Army's laboratory resources and research experts at WRAIR will aid in development of APT's PhageBank phage library, APT said.
It also expands the company's relationship with the U.S. Department of Defense and affirms its commitment to providing antimicrobial resistance treatment options to war fighters and veterans, according to APT.